Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
258
-
Total 13F shares, excl. options
-
91.4M
-
Shares change
-
-751K
-
Total reported value, excl. options
-
$4.34B
-
Value change
-
-$45.1M
-
Put/Call ratio
-
0.32
-
Number of buys
-
115
-
Number of sells
-
-127
-
Price
-
$47.48
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q3 2025
328 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q3 2025.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 258 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.4M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (6.28M shares), GENERAL ATLANTIC, L.P. (5.73M shares), BlackRock, Inc. (5.7M shares), RTW INVESTMENTS, LP (5.48M shares), VANGUARD GROUP INC (4.53M shares), WELLINGTON MANAGEMENT GROUP LLP (4.25M shares), Deep Track Capital, LP (4M shares), Avoro Capital Advisors LLC (3.96M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.81M shares), and STATE STREET CORP (3.41M shares).
This table shows the top 258 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.